RANOLAZINE
Generic: RANOLAZINE
Ascend LaboratoriesManufacturer
ORALRoute
RANOLAZINEActive Substance
2020-11-30Original Approval
RANOLAZINE is FDA application ANDA209953, sponsored by ALKEM LABS LTD. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2025-03-13
Ranolazine Extended-Release Tablets 1000mg, 60-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals LimiteCGMP Deviations
Class II2023-10-23
Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals LimFailed Dissolution Specifications: Out of specification for dissolution.
Class II2026-09-17
Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., BridgewaterFailed Dissolution Specifications: below specification
Top Reported Reactions
1
DEATH
831 reports
2
MYOCARDIAL INFARCTION
650 reports
3
CHEST PAIN
622 reports
4
ANGINA PECTORIS
599 reports
5
STENT PLACEMENT
582 reports
6
DYSPNOEA
447 reports
7
DIZZINESS
438 reports
8
FALL
387 reports
9
CEREBROVASCULAR ACCIDENT
356 reports
10
CARDIAC DISORDER
311 reports